KONFERENCJA NAUKOWA
„GENETYKA KLINICZNA NOWOTWORÓW 2019”
CLINICAL GENETIC of CANCER 2019
Serdecznie dziękujemy wszystkim uczestnikom za wzięcie udziału w Międzynarodowej Konferencji „Genetyka Kliniczna Nowotworów 2019”, która odbyła się w dniach 19-20 września 2019 r. Mamy nadzieję, że spełniła ona Państwa oczekiwania, zarówno pod względem merytorycznym, jak i organizacyjnym. Jeżeli mają Państwo jakiekolwiek uwagi na temat konferencji, uprzejmie prosimy kierować je na adres: konferencjanowotworydziedziczne@wp.pl
Zapraszamy Państwa do udziału w Konferencji Naukowej w przyszłym roku.
Tytuły i kolejność abstraktów:
- Opportunistic screening in diagnostics for cancer predisposition: should we? (R. Sijmons, Netherlands)
- Comprehensive mismatch repair gene panel screening identifies variants in patients with Lynch-like syndrome. (R. Scott, Australia)
- Hereditary predisposition to acute myeloid leukemia and other myeloid malignancies. (O. Haus, Poland)
- Clinical applications of methylation biomarkers. (T. Wojdacz, Poland)
- Treatment of hereditary cancers: the year 2019 update. ( Imyanitov, Russia)
- Genetic variation of response to chemotherapy treatment of breast cancer. (E. Grzybowska, Poland)
- Spectrum of BRCA1/2 nonfounder mutations in Baltic region. (A. Irmejs, Latvia)
- Survival of breast cancer patients withCHEK2 (J. Tomiczek-Szwiec, Poland)
- Associations between germline genetic polymorphisms and toxicity of breast cancer chemotherapy. (J. Pamuła-Piłat, Poland)
- Anemia in the breast cancer patient with PALB2 mutation after radiotherapy – a case report. (M. Lisik, Poland)
- The application of ctDNA based tests in ovarian cancer diagnostic and research. (M. Ratajska, Poland)
- Prevalence of germline TP53 mutations among early – onset breast cancer patients from Polish population. (K. Malińska, Poland)
- Young Lynch Syndrome patients and CRC prevention in low incidence population of Lithuania. (P. Elsakov, Lithuania)
- Cancer stemness as hallmark of oncogenic progression. (M. Wiznerowicz, Poland)
- The spectrum of mutations predisposing to familial breast cancer in Poland. (C. Cybulski, Poland)
- Allelic modification of breast cancer risk in women with an NBN mutation.
(B. Rusak, Poland) - Association of CHEK2, PALB2, RAD51C mutations with borderline ovarian tumors in patients from Polish population. (A. Łukomska, Poland)
- Inherited variants in XRCC2 and the risk of breast cancer. (W. Kluźniak, Poland)
- Phenotype of NTHL1 gene mutations. (A. Pławski, Poland)
- Germline variants in ACD, TERF2IP and POT1 genes in patients with melanoma in the Polish population. (J. Deptuła, Poland)
- Analysis of how much Polish people know about the impact of air pollution on human health. (J. Koprowicz, Poland)
- Influence of the level of selected heavy metals on overall survival in lung cancer. (S. Pietrzak, Poland)
- Cadmium blood level as cancer risk marker in BRCA1 carriers. (R. Derkacz, Poland)
- SELINA – the latest advances. (J. Lubiński, Poland)
- Clinical trials in BRCA1 carriers. (T. Huzarski, Poland)
- Cis-platinum in the treatment of BRCA1 – dependant cancers. (Jan Lubiński, Poland)
- The usability of cytological and molecular tests in the pre-clinical diagnostics of non-invasive urothelial carcinoma. Case study. (B. Kałużewski, Poland)
- Zinc serum level in correlation with GPX1, SOD2 and CAT genotypes as prognostic marker of survival in laryngeal cancer. (Jakub Lubiński, Poland)
- Micro – and macroelements as diagnostic tests in oncology. (W. Marciniak, Poland)
- Cooperation of a clinician, molecular biologist and clinical geneticist. From hobby activities to predictive factor – how drugs change the world. (M. Mądry, Poland)
Formularz rejestracyjny Program konferencji Wzór streszczenia Mapka dojazdu